FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387598469> ?p ?o ?g. }

• W4387598469 abstract "Ruxolitinib cream is a topical formulation of ruxolitinib, a selective inhibitor of Janus kinase (JAK) 1 and JAK2. In two phase 3 studies in adults and adolescents (aged ≥12 years) with atopic dermatitis (AD; TRuE-AD1/TRuE-AD2), significantly more patients who applied ruxolitinib cream versus vehicle cream achieved Investigator's Global Assessment treatment success (IGA-TS; IGA score of 0/1 with ≥2-point improvement from baseline) at week 8 (primary endpoint). This post hoc analysis evaluated the efficacy, safety, and disease control of ruxolitinib cream in patients with AD who did not achieve IGA-TS at week 8. Patients in TRuE-AD1/TRuE-AD2 (N = 1249) were randomized 2:2:1 to apply twice-daily 0.75% ruxolitinib cream, 1.5% ruxolitinib cream, or vehicle cream for 8 weeks followed by a long-term safety period in which patients applied ruxolitinib cream as needed. In this pooled analysis, clinically meaningful response thresholds included ≥50% improvement in the Eczema Area and Severity Index, ≥2-point reduction in the Itch Numerical Rating Scale, ≥4-point improvement in the Dermatology Life Quality Index (DLQI) or ≥6-point improvement in Children's DLQI, and ≥1-point reduction in IGA from baseline. Among patients who did not achieve IGA-TS at week 8 (n = 584), significantly more patients who applied either strength ruxolitinib cream versus vehicle achieved each response threshold at week 8. A response in ≥1 clinically meaningful endpoint was achieved in significantly more patients who applied ruxolitinib cream (93.4%/90.9% for 0.75%/1.5% ruxolitinib cream, respectively) versus vehicle (69.0%, both P < 0.0001). Progressive improvements in disease control were observed, with many patients achieving IGA-TS by week 52 (55.2%/56.3% for 0.75%/1.5% ruxolitinib cream, respectively). Ruxolitinib cream was well tolerated during the 52-week study in this patient population. Taken together, these results demonstrate that most patients with AD who did not achieve IGA-TS at week 8 have clinically meaningful responses to ruxolitinib cream, and continued therapy beyond 8 weeks could result in additional benefit." @default.
• W4387598469 created "2023-10-14" @default.
• W4387598469 creator A5015905197 @default.
• W4387598469 creator A5051150897 @default.
• W4387598469 creator A5058903008 @default.
• W4387598469 creator A5065252914 @default.
• W4387598469 creator A5071907436 @default.
• W4387598469 creator A5077565661 @default.
• W4387598469 creator A5079275603 @default.
• W4387598469 creator A5080237247 @default.
• W4387598469 date "2023-10-13" @default.
• W4387598469 modified "2023-10-14" @default.
• W4387598469 title "Clinically relevant improvements in adults and adolescents with atopic dermatitis who did not achieve Investigator's Global Assessment treatment success following 8 weeks of ruxolitinib cream monotherapy" @default.
• W4387598469 cites W2058562555 @default.
• W4387598469 cites W2079645940 @default.
• W4387598469 cites W2192134383 @default.
• W4387598469 cites W2820763047 @default.
• W4387598469 cites W2895509206 @default.
• W4387598469 cites W2904559265 @default.
• W4387598469 cites W2914603675 @default.
• W4387598469 cites W2916274906 @default.
• W4387598469 cites W2954110843 @default.
• W4387598469 cites W2979754363 @default.
• W4387598469 cites W2981554886 @default.
• W4387598469 cites W3041099338 @default.
• W4387598469 cites W3047057201 @default.
• W4387598469 cites W3159897478 @default.
• W4387598469 cites W3179979665 @default.
• W4387598469 cites W3207234169 @default.
• W4387598469 cites W4211013257 @default.
• W4387598469 cites W4220885146 @default.
• W4387598469 cites W4224237183 @default.
• W4387598469 cites W4283700467 @default.
• W4387598469 cites W4294754906 @default.
• W4387598469 cites W4296164016 @default.
• W4387598469 cites W4310015221 @default.
• W4387598469 cites W4313627938 @default.
• W4387598469 doi "https://doi.org/10.1111/1346-8138.16975" @default.
• W4387598469 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37830436" @default.
• W4387598469 hasPublicationYear "2023" @default.
• W4387598469 type Work @default.
• W4387598469 citedByCount "0" @default.
• W4387598469 crossrefType "journal-article" @default.
• W4387598469 hasAuthorship W4387598469A5015905197 @default.
• W4387598469 hasAuthorship W4387598469A5051150897 @default.
• W4387598469 hasAuthorship W4387598469A5058903008 @default.
• W4387598469 hasAuthorship W4387598469A5065252914 @default.
• W4387598469 hasAuthorship W4387598469A5071907436 @default.
• W4387598469 hasAuthorship W4387598469A5077565661 @default.
• W4387598469 hasAuthorship W4387598469A5079275603 @default.
• W4387598469 hasAuthorship W4387598469A5080237247 @default.
• W4387598469 hasBestOaLocation W43875984691 @default.
• W4387598469 hasConcept C112392421 @default.
• W4387598469 hasConcept C126322002 @default.
• W4387598469 hasConcept C16005928 @default.
• W4387598469 hasConcept C168563851 @default.
• W4387598469 hasConcept C197934379 @default.
• W4387598469 hasConcept C203092338 @default.
• W4387598469 hasConcept C2776112149 @default.
• W4387598469 hasConcept C2776173921 @default.
• W4387598469 hasConcept C2776233030 @default.
• W4387598469 hasConcept C2778329239 @default.
• W4387598469 hasConcept C2778690821 @default.
• W4387598469 hasConcept C2779134260 @default.
• W4387598469 hasConcept C2780007613 @default.
• W4387598469 hasConcept C2780076729 @default.
• W4387598469 hasConcept C2780699399 @default.
• W4387598469 hasConcept C71924100 @default.
• W4387598469 hasConceptScore W4387598469C112392421 @default.
• W4387598469 hasConceptScore W4387598469C126322002 @default.
• W4387598469 hasConceptScore W4387598469C16005928 @default.
• W4387598469 hasConceptScore W4387598469C168563851 @default.
• W4387598469 hasConceptScore W4387598469C197934379 @default.
• W4387598469 hasConceptScore W4387598469C203092338 @default.
• W4387598469 hasConceptScore W4387598469C2776112149 @default.
• W4387598469 hasConceptScore W4387598469C2776173921 @default.
• W4387598469 hasConceptScore W4387598469C2776233030 @default.
• W4387598469 hasConceptScore W4387598469C2778329239 @default.
• W4387598469 hasConceptScore W4387598469C2778690821 @default.
• W4387598469 hasConceptScore W4387598469C2779134260 @default.
• W4387598469 hasConceptScore W4387598469C2780007613 @default.
• W4387598469 hasConceptScore W4387598469C2780076729 @default.
• W4387598469 hasConceptScore W4387598469C2780699399 @default.
• W4387598469 hasConceptScore W4387598469C71924100 @default.
• W4387598469 hasFunder F4320317544 @default.
• W4387598469 hasLocation W43875984691 @default.
• W4387598469 hasLocation W43875984692 @default.
• W4387598469 hasOpenAccess W4387598469 @default.
• W4387598469 hasPrimaryLocation W43875984691 @default.
• W4387598469 hasRelatedWork W2003620798 @default.
• W4387598469 hasRelatedWork W2766528424 @default.
• W4387598469 hasRelatedWork W3196069457 @default.
• W4387598469 hasRelatedWork W3204561650 @default.
• W4387598469 hasRelatedWork W4236869562 @default.
• W4387598469 hasRelatedWork W4237621822 @default.
• W4387598469 hasRelatedWork W4285984819 @default.
• W4387598469 hasRelatedWork W4295338524 @default.
• W4387598469 hasRelatedWork W4313379830 @default.
• W4387598469 hasRelatedWork W4367553261 @default.
• W4387598469 isParatext "false" @default.

• next